Cayman, Akadeum to revolutionize cell isolation for cell and gene therapy

DINAMIQS inaugurates new cGMP viral vector manufacturing facility in Switzerland

The new site enables end-to-end production of viral vector gene therapies

Fujifilm Biotechnologies opens cell culture manufacturing site in North Carolina

Represents one of the largest cell culture biomanufacturing sites in North America, which will employ 1,400 people by 2031

Ascletis reports positive phase Ib results for oral GLP-1R agonist ASC30 at EASD 2025

The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States

Merck opens €150 million manufacturing facility in Ireland

Merck opens first climate-neutral manufacturing facility in Ireland

ProBioGen to spearhead GMP manufacturing at Berlin’s gene & cell therapy hub

ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit

Ascletis' ASC30 obesity drug shows 75-day half-life in US Study

Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity

Novo Nordisk’s amylin therapy cagrilintide shows significant weight loss in phase 3 trial

Cagrilintide represents a novel approach to obesity management

FDA approves Corstasis’ bumetanide nasal spray to treat edema in heart, liver, and kidney disease

Novo Nordisk to cut 9,000 jobs globally

Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients